局部晚期非小细胞肺癌同步放化疗并序贯化疗与单纯序贯放化疗的对比研究
DOI: 10.3971/j.issn.1000-8578.2015.06.016
Keywords: A Meta-analysis,NSCLC的疫苗治疗研究进展,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Effect of Vascular Endothelial Cadherin on Invasion and Metastasis of Non-small Cell Lung Cancer Cells and Related Mechanism,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Prognosis of Clinical Stage ⅢA(N2) Non-small Cell Lung Cancer Patients Received Radiotherapy,Quality Assessment of Reports of Randomized Controlled Trials Published in Chinese in Field of Non-small Cell Lung Cancer in China,Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer,Review of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adjuvant Treatment of Non-small Cell Lung Cancer,Evaluation of Ligand-targeted PCR Method in Detecting Tumor Cell Levels in Pleural Effusion of Patients with Non-small Cell Lung Cancer,Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
Abstract:
摘要 目的 观察局部晚期非小细胞肺癌（NSCLC）接受调强放疗（IMRT）联合同步吉西他滨和卡铂方案（GC）化疗与序贯放化疗的近、远期疗效和不良反应。方法 回顾性分析不能进行手术治疗和拒绝手术治疗的局部晚期NSCLC患者65例，其中同步放化疗并序贯化疗组给予IMRT同步联合GC治疗者32例，单纯序贯放化疗组为33例给予IMRT后序贯GC治疗。通过统计分析比较两组之间的近期有效率、远期生存率和不良反应。结果 两组均完成治疗，随访率100%，同步放化疗并序贯化疗组近期有效率为75%，单纯序贯放化疗组为66.7% ，两组比较差异有统计学意义（P＜0.05）。两组1、3年生存率相比较，同步放化疗并序贯化疗组为68. 2% 、20. 5% ；单纯序贯放化疗组为 50. 1% 、11.3%；同步放化疗并序贯化疗组明显优于单纯序贯放化疗组（P＜0.05）。两组不良反应情况对比，差异无统计学意义（P＞0.05）。结论 IMRT同步联合GC方案并序贯化疗治疗局部晚期NSCLC，可以提高患者的远期生存率且不良反应可耐受
Full-Text
